# Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

> **NCT06268665** · PHASE2 · RECRUITING · sponsor: **University of California, Davis** · enrollment: 86 (estimated)

## Conditions studied

- Breast Cancer
- Breast Cancer Stage I
- Breast Cancer Stage II
- Breast Cancer Stage III
- Breast Cancer Stage IV
- Invasive Breast Cancer
- Ovarian Cancer
- Ovarian Cancer Stage 1
- Ovarian Cancer Stage II
- Ovarian Cancer Stage III
- Ovarian Cancer Stage IV
- Ovarian Cancer Stage IA
- Ovarian Cancer Stage IB
- Ovarian Cancer Stage IC
- Ovarian Cancer Stage 2
- Ovarian Cancer Stage 3
- Ovarian Cancer Stage IIIb
- Ovarian Cancer Stage IIIC
- Breast Cancer Stage IIIA
- Breast Cancer Invasive
- Breast Cancer, Stage IA
- Breast Cancer, Stage IB
- Breast Cancer Stage IIA
- Breast Cancer Stage IIB
- Breast Cancer Stage IIIB
- Breast Cancer Stage IIIc
- Cancer, Breast
- Tumors, Breast
- Mammary Cancer
- Mammary Carcinoma
- Breast Carcinoma
- Breast Neoplasm
- Malignant Breast Neoplasm
- Malignant Tumor of Breast
- Cancer of Ovary
- Ovary Cancer
- Ovary Neoplasm

## Interventions

- **DRUG:** Tart Cherry Juice

## Key facts

- **NCT ID:** NCT06268665
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-15
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06268665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06268665, "Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06268665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*